Management issues in the metabolic syndrome

Journal of Association of Physicians of India

Volumn 54, Issue OCT., 2006, Pages 797-810

  Deedwania, P C ^a   Gupta, R ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Monilek Hospital and Research Centre   (India)

Author keywords

[No Author keywords available]

Indexed keywords

DIET; DRUG THERAPY; HUMAN; LIFESTYLE; METABOLIC SYNDROME X; REVIEW;

DIET; DRUG THERAPY; HUMANS; LIFE STYLE; METABOLIC SYNDROME X;

EID: 33749864985     PISSN: 00045772     EISSN: 00045772     Source Type: Journal    
DOI: None     Document Type: Review

References (79)

1. nd Ed. Oxford. Oxford University Press. 2005;18-31.
2. Kylin E. Studien uber das hypertonie-hyperglykamiehyperurikamie syndrome. Zentralblatt fur Innere Medizin 1923;44:105-27.
3. Himsworth HP. The mechanism of diabetes mellitus. Lancet 1939; ii:1-6.
4. Reaven G. Role of insulin resistance in human disease. Diabetes 1988;37:1595-1607.
5. Reaven G. Insulin resistance, type 2 diabetes and cardiovascular disease: the end of the beginning. Circulation 2005;112:3030-32.
6. Lemieux I, Pascot A, Couillard C, et al. Hypertriglyceridemic waist: a marker of atherogenic metabolic triad in men? Circulation 2000;102:179-84.
7. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005;365:1415-28.
8. National Cholesterol Education Program. Executive summary of the third report of the National Cholesterol Education Program Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel-III). JAMA 2001;285:2486-97.
9. Alberti KGMM, Zimmet P, Shaw J. For the IDF Epidemiology Task Force Consensus Group. The metabolic syndrome; a new worldwide definition. Lancet 2005;366:1059-62.
10. nd Ed. New York McGraw Hill. 2005;456-72.
11. Dandona P, Aljada A, Chaudhuri A, Mohanty P, Garg R. Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation 2004;111:1448-54.
12. Misra A, Chudhary D, Vikram NK, et al. Insulin resistance and clustering of atherogenic risk factors in women belonging to low socioeconomic strata in urban slums of north India. Diab Res Clin Pract 2002;56:73-75.
13. Deepa R, Shantirani CS, Premalatha G, Sastry NG, Mohan V. Prevalence of insulin resistance syndrome n a selected south Indian population. Ind J Med Res 2002;115:118-27.
14. Ramachandran A, Snehalatha C, Satyavani K, Sivasankari S, Vijay V. Metabolic syndrome in urban Asian Indians adults: a population study using modiied ATP III criteria. Diab Res Clin Pract 2003;60:199-204.
15. Gupta R, Deedwania PC, Gupta A, Rastogi S, Panwar RB, Kothari K. Prevalence of metabolic syndrome in an Indian urban population. Int J Cardiol 2004;97:257-61.
16. Misra A, Vikram NK. Insulin resistance syndrome (metabolic syndrome) and obesity in Asian Indians: evidence and implications. Nutrition 2004;20:482-91.
17. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/ National Heart Lung and Blood Institute scientific statement. Circulation 2005;112:2735-52.
18. Gupta R, Sarna M, Thanvi J, Rastogi P, Kaul V, Gupta VP. High prevalence of multiple coronary risk factors in Punjabi Bhatia community: Jaipur Heart Watch-3. Indian Heart J 2004;57:646-52.
19. Gupta R, Deedwania PC. The metabolic syndrome and obesity. In: Mohan V, Rao GHR. Editors. Diabetes in South Asia In Press.
20. Yanovski SZ, Yanovski JA. Obesity. N Engl J Med 2002;346:591-602.
21. Haslam DW, James WPT. Obesity. Lancet 2005;366:1197-1209.
22. Miranda PJ, DeFronzo RA, Califf RM, Guyton JR. Metabolic syndrome: evaluation of pathological and therapeutic outcomes. Am Heart J 2005;149:20-32.
23. Toumilheto J, Lindstrom J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus with lifestyle intervention or metformin. N Engl J Med 2001;344:1343-50.
24. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403.
25. Stern L, Iqbal N. Seshadri P, et al. The effects of low carbohydrate versus conventional weight loss diets in severely obese adults: one year follow-u of a randomized trial. Ann Intern Med 2004;140:778-85.
26. Dansinger ML, Gleason JA, Griffith JL, Selker HP, Schaefer EJ. Comparison of Atkins, Ornish, Weight Watchers, and Zone diets for weight loss and heart disease risk reduction. JAMA 2005;293; 43-53.
27. Knowler WC, Hamman RF, Edelstein SL, et al. Diabetes Prevention Program Research Group. Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program. Diabetes 2005;54:1150-56.
28. Diabetes Prevention Program Research Group. Role of insulin sensitivity and secretion in the evolution of type 2 diabetes in the Diabetes Prevention Program. Diabetes 2005;54:2404-14.
29. Ornish D, Brown SE, Scherwitz LW, et al. Can lifestyle changes reverse heart disease? Lancet 1990;336:129-33.
30. Patel C, Marmot MG, Terry DJ, et al. Trial of relaxation in reducing coronary risk: four year follow-up. BMJ 1985;290:2001-07.
31. Manchanda SC, Narang R, Reddy KS, et al. Retardation of coronary atherosclerosis with yoga lifestyle intervention. J Assoc Physicians India 2000;48:687-94.
32. Damodaran A, Malathi A, Patil N, et al. Therapeutic potential of yoga practices in modifying cardiovascular risk profile. J Assoc Physicians India 2002;50:633-40.
33. Vijayraghavan K, Deedwania PC. The renin angiotensin system as a therapeutic target to prevent diabetes and its complications. Cardiol Clin 2005;23:165-83.
34. Deedwania PC, Fonesca VA. Diabetes, prediabetes, and cardiovascular risk: shifting the paradigm. Am J Med 2005;118:939-47.
35. Krejs GJ. Metabolic benefits associated with sibutramine therapy. Int J Obesity 2002;26(Suppl 4):S34-S37.
36. Didangelos TP, Thanapoulou AK, Bousboulas SH, et al. The orlistat and cardiovascular risk profile in patients with the metabolic syndrome and type 2 diabetes (ORLICARDIA) study. Curr Med Res Opin 2004;20:1393-1401.
37. Hseih CJ, Wang PW, Liu RT, et al. Orlistat for obesity: benefits beyond weight loss. Diab Res Clin Pract 2005;67:78-83.
38. Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L. Xenical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study or orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004;27:155-61.
39. Pagotto U, Pasquali R. Fighting obesity and associated risk factors by antagonizing cannabinoid type 1 receptors. Lancet 2005;365:1363-64.
40. Van Gaal LF, Rissanen AM, Scheen AJ, Zigler O, Rossner S, for the RIO-Europe Study Group. Effects of the cannabinoids-1 receptor blocker rimonabant on wight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005;365:1389-97.
41. Despres JP, Golay A, Sjostrom L, Rimonabant in Obesity-Lipids (RIO-Lipids) Study Group. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005;353:2121-34.
42. Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J, for RIO-North America Study Group. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients. JAMA 2006;295:761-75.
43. Kelley DE. Themodynamics, liposuction and obesity. N Engl J Med 2004;350:2542-44.
44. Klein S, Fontana L, Young VL, et al. Absence of an effect of liposuction on insulin action and risk factors for coronary heart disease. N Engl J Med 2004;350:2449-557.
45. Sjostrom L, Lindroos AK, Peltonen M, et al. Lifestyle, diabetes and cardiovascular riks factors 10 years after bariatric surgery. N Engl J Med 2004;351:2683-93.
46. Wolfe BM, Morton JM. Weighing in on bariatric surgery: procedure use, readmission rates and mortality. JAMA 2005;294; 1960-63.
47. Grundy SM. Small LDL, atheogernic dyslipidemia and the metabolic syndrome. Circulation 1997;95:1-4.
48. Foeber JC, Frohlich JJ, Gerest JJ, et al. Recommendations for the management and treatment of dyslipidemia. Report of the working group of hypercholesterolemia and other dyslipidemias. CMAJ 2000;162:1441-47.
49. Deedwania PC. TNT study and metabolic syndrome. Circulation 2005;112(Suppl A).Abstract.
50. Cottrell DA, Marshall BJ, Falko JM. Therapeutic approaches to dyslipidemia in diabetes mellitus and metabolic syndrome. Curr Opin Cardiol 2003;18:301-08.
51. Davidson MH, Toth PP. Combination therapy in the management of complex dyslipidemias. Curr Opin Lipid 2004;15:423-31.
52. Paucillo P, Borgnino C, Paoletti R, et al. Efficacy and safety of a combination of fluvastatin and bezafibrate in patients with mixed hyperlipidemia (FACT study). Atherosclerosis 2000;150:429-36.
53. Han SH, Quon MJ, Koh KK. Beneficial vascular and metabolic effects of peroxisome proliferator activated receptor-alpha activators. Hypertension 2005;46:1086-92.
54. The FIELD study investigators. Effects for long-term fenofibrate therapy in cardiovascular events in 9795 people with type 2 diabetes mellitus (The FIELD study): randomized controlled trial. Lancet 2005;366:1849-61.
55. Sharma M, Sharma DR, Singh V, et al. Evaluation of efficacy and safety of fixed dose lovastatin-niacin combination in hyperlipidemic patients: a multicentric study. Vasc Health Risk Management 2006;2:87-93.
56. Libby P. The forgotten majority: unfinished business in cardiovascular risk reduction. JACC 2005;46:1225-28.
57. Brousseau ME, Schaefer EJ, Wolfe ML, et al. Effects of an inhibitor of cholesterol ester transfer protin on HDL cholesterol. N Engl J Med 2004;350:1505-15.
58. Barted PJ, Kastelein JJP. Targeting cholesteryl ester transfer rotein for the prevention and management of cardiovascular disease. JACC 2006;47:492-99.
59. Esler MD. Metabolic syndrome and hypertension: what are the outstanding problems? Dialogues Cardiovasc Med 2004;9:167-72.
60. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the joint national committee on prevention, detection, evaluation and treatment of high blood pressure: the JNC-7 report. JAMA 2003;289:2560-72.
61. Barnett AH, Bain SC, Bouter P, et al. Diabetics exposed to telmisartan and enalapril study group. Angiotensin receptor blockade versus converting enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 2004;351:1952-61.
62. Eriksson KF, Lindgrade F. Prevention of type 2 diabetes mellitus by diet and physical exercise. The 6-year Malmo feasibility study. Diabetologia 1991;34:891-98.
63. Eriksson KF, Lindgrade F. No excess of 12-year mortality in men with impaired glucose tolerance who participated in the Malmo preventive trial with diet and exercise. Diabetologia 1998;41:1010-16.
64. Pan XR, Li GW, Hu YH, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance: the Da Qing IGT and Diabetes Study. Diabetes Care 1997;20:537-44.
65. Diabetes Prevention Program Research Group. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention Program. Diabetes Care 2005;28:888-94.
66. Chiasson JL, Josse RG, Gomis R, et al. Acarbose for prevention of type 2 diabetes mellitus: STOP-NIDDM randomized trial. Lancet 2002;359:2072-77.
67. Buchanan TA, Xiang AH, Peters RK, et al. Preservation of pancreatic -cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high risk Hispanic women. Diabetes 2002;51:2796-803.
68. Rajagopalan R, Iyer S, Khan M. Effect of pioglitazone on metabolic syndrome risk factors: results of double blind, multi-center, randomized clinical trials. Curr Med Res Opin 2005;21:163-72.
69. Dormandy JA, Charbonnel B, Eckland DJA, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomized controlled trial. Lancet 2005;366:1279-89.
70. Etgen GJ, Oldham BA, Johnson WT, et al. A tailored therapy for the metabolic syndrome: the dual PPAR alpha/gamma agonist LY463608 ameliorates insulin resistance and diabetic hyperglycemia wile improving cardiovascular risk factors in preclinical models. Diabetes 2002;51:1083-87.
71. Gerstein H. The ORIGIN study. At: www.cmeondiabetes.com/pub/the.origin. study.php. Accessed 16 March 2006.
72. Patrono C, Garcia-Rodriguez LA, Landolfi R, Baigent C. Low dose aspirin for the prevention of atherothrombosis. N Engl J Med 2005;353:2373-83.
73. Wald N, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ 2003;326:1149-55.
74. Hippisley-Cox J, Coupland C. Effect of combinations of drugs on all cause mortality in patients with ischemic heart disease: nested case-control analysis. BMJ 2005;330:1059-63.
75. Gupta R, Prakash H, Gupta RR. Economic issues in coronary heart disease prevention in India. J Hum Hypertens 2005;19:655-57.
76. Combination Pharmacotherapy and Public Health Research Working Group. Combination pharmacotherapy for cardiovascular disease. Ann Intern Med 2005;1443:593-99.
77. Gupta R. Burden of coronary heart disease in India. Ind Heart J 2005;57:632-38.
78. Reddy KS, Shah B, Varghese C, Ramadoss A. Responding to the threat of chronic diseases in India. Lancet 2005;336:1744-49.
79. Grundy SM. Metabolic syndrome: connecting and reconciling cardiovascular and diabetes worlds. JACC 2006;47:1093-1100.